Polycystic Ovaries Research Today is a free monthly online journal that collates and summarizes the latest research about Polycystic Ovaries, including details on treatment, symptoms, polycystic ovary syndrome, infertility. | ||||||
|
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G 2nd Department of Obstetrics and Gynecology, Division of Human Reproduction, Aristotle University of Thessaloniki, Thessaloniki, Greece. OBJECTIVE: To investigate the combined effect of diet and orlistat, for 24 weeks, on anthropometric features, hormonal parameters, and indices of insulin resistance in obese women with polycystic ovary syndrome (PCOS) and in obese women without the syndrome. DESIGN: Prospective clinical study. SETTING: Department of obstetrics and gynecology in a major university in Greece. PATIENT(S): Eighteen selected women with PCOS were matched for age and body mass index with 14 obese control women. INTERVENTION(S): Subjects were prescribed an energy-restricted diet, and orlistat (120 mg, 3 times per d) was administered to all subjects for 24 weeks. MAIN OUTCOME MEASURE(S): At baseline, week 12, and week 24, after an overnight fast, blood samples were collected, and serum levels of FSH, LH, PRL, T, Delta(4)A, DHEAS, 17 alpha-hydroxyprogesterone, sex hormone-binding globulin, glucose, and insulin were measured. RESULT(S): Testosterone levels were significantly decreased with treatment in women with PCOS; this decrease was attributed to the first trimester, whereas T levels did not change during the second 12-week period. In women with PCOS, insulin levels and HOMA-IR values were decreased during the first 12 weeks, whereas no significant change was observed during the second trimester. CONCLUSION(S): Orlistat administration, combined with diet, for 24 weeks, resulted in significant weight loss and improvement of insulin resistance in obese women, with or without PCOS. Moreover, T levels were significantly decreased in women with PCOS. There appears to be a trend during the first 12-week period for greater improvement of metabolic and hormonal parameters in women with PCOS. Published 14 April 2008 in Fertil Steril, 89(4): 899-906. Articles on Polycystic Ovaries published 31 March 2008: Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes, 57(4): 801-8. OBJECTIVE: Polycystic ovary syndrome (PCOS) is associated with insulin resistance and obesity. Recent studies have shown that plasma omentin-1 levels decrease with obesity. Currently, no data exist on the relative expression and regulation of omentin-1 in adipose tissue of women with PCOS. The objective of this study was to assess mRNA and protein levels of omentin-1, including circulating omentin-1, in omental adipose tissue of women with PCOS and matched control subjects. Ex vivo and in vivo ... [Abstract] [Full-text] Articles on Polycystic Ovaries published 25 March 2008: Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol, 158(4): 525-31. BACKGROUND: Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) have been considered as important mediators of vascular remodeling and plaque instability. The formation of a complex with NGAL and MMP-9 is crucial for atherotic plaque erosion and thrombus formation. In women with polycystic ovary syndrome (PCOS), the incidence of cardiovascular clinical events is not increased, despite the fact that they display a wide spectrum of risk factors. Since the ... [Abstract] [Full-text] Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. Eur J Endocrinol, 158(4): 517-23. OBJECTIVE: Adiposity, insulin resistance (IR), and hyperandrogenism are features of polycystic ovary syndrome (PCOS). Retinol-binding protein 4 (RBP4) secreted from adipose and liver tissues has been linked to IR. The impact of RBP4 on IR in PCOS and its usability to identify women with metabolic syndrome (MS) or impaired glucose tolerance ((IGT) or diabetes) were investigated. DESIGN: Plasma RBP4 was determined in 115 consecutive PCOS women. Associations with IR, body composition, and ... [Abstract] [Full-text] Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur J Endocrinol, 158(4): 511-6. OBJECTIVE: Abnormal ghrelin regulation may influence the development of obesity-associated conditions including polycystic ovary syndrome (PCOS). Our aim was to compare ghrelin regulation between PCOS cases and controls. DESIGN: We compared serum ghrelin (total) levels, fasting and 30-min post-oral (75 g) glucose load, between 50 PCOS cases and 28 female controls, including 22 body mass index (BMI)/fat mass-matched pairs. All subjects were of UK British/Irish origin. METHODS: Measurements ... [Abstract] [Full-text] Articles on Polycystic Ovaries published 21 March 2008: Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab, 4(4): 215-22. Polycystic ovary syndrome (PCOS) is a complex disorder comprising both hormonal and metabolic abnormalities that include impaired glucose tolerance, type 2 diabetes, vascular disease, dyslipidemia, and obstructive sleep apnea. Insulin resistance is a central pathogenetic factor in PCOS that seems to result from a post-receptor-binding defect in insulin action. Insulin resistance and the consequent development of hyperinsulinemia contribute to the constellation of cardiometabolic abnormalities ... [Abstract] [Full-text] Articles on Polycystic Ovaries published 11 March 2008: Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril, 89(3): 505-22. The treatment of infertile women with polycystic ovary syndrome (PCOS) is surrounded by many controversies. On the basis of the currently available evidence, a group of experts reached a consensus regarding the therapeutic challenges raised in these women. Before any intervention is initiated, preconceptional counseling should be provided emphasizing the importance of lifestyle, especially weight reduction and exercise in overweight women, smoking, and alcohol consumption. The recommended ... [Abstract] [Full-text] Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril, 89(3): 625-34. OBJECTIVE: To prospectively assess whether metformin diet safely provides primary and secondary prevention of gestational diabetes (GD). DESIGN: Assess development of GD on metformin diet. SETTING: Outpatient clinical research center. PATIENT(S): One hundred forty-two nondiabetic women with polycystic ovary syndrome (PCOS) who had at least one live-birth (LB) pregnancy on metformin diet (172 pregnancies, 180 LBs). INTERVENTION(S): Women were given 26% protein, 44% carbohydrate diets, without ... [Abstract] [Full-text] Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril, 89(3): 642-8. OBJECTIVE: To assess message expression of adiponectin and leptin in visceral and SC fat in women with polycystic ovary syndrome (PCOS) and in control women. DESIGN: Prospective clinical trial. SETTING: Academic medical centers in Mexico City, Mexico and New York, New York. PATIENT(S): Women with PCOS and control women. INTERVENTION(S): Surgical biopsies of visceral (omental) and subcutaneous (SC) adipose tissue, fasting blood samples, and ultrasound measurements of visceral and SC fat. MAIN ... [Abstract] [Full-text] © 2004-2008 Polycystic Ovaries Research Today. All Rights Reserved. |
| ||||
